Abbott Laboratories (NYSE:ABT) Rating Maintained
In an analyst note published on today, BMO Capital Markets reaffirmed their “Market Perform” rating on Abbott Laboratories (NYSE:ABT)’s stock. The target means a potential downside of -91.06 % from company’s close price.
According to data compiled by Thomson Reuters, Abbott Laboratories (NYSE:ABT)’s stock is covered by 15 equity analysts across the Street, with 0 analysts giving it a Sell rating, 14 a Buy rating, while 6 consider it a Hold. The 12-month consensus target price for the stock is $46.73, which reflects an downside potential of 16.21% over the current price.
Arrow Capital Management Llc had the largest stake with ownership of 264,455 shares as of Q2 2015 for 14.26% of the US equity exposure. Flossbach Von Storch Ag is another bull as the investment professional who is owning 14.30 million shares of Abbott Laboratories or 10.09% of their US equity exposure. In addition, Mondrian Investment Partners Ltd have 7.25% of their US equity exposure invested in the company for 7.00 million shares. The Delaware-based fund Brandywine Trust Co revealed it had bought a stake worth about 6.96% of the investment professional’s stock portfolio in Abbott Laboratories. The Norway-based fund Sector Gamma As is also positive about the stock, possessing 224,855 shares or 6.52% of their US equity exposure.
Abbott Laboratories (NYSE:ABT) Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Abbott Laboratories (NYSE:ABT) traded up 1.27% on 19 October, hitting $55.77. A total of shares of the company’s stock traded hands. This is down from average of 5.97 million shares. Abbott Laboratories has a 52 week low of $37.38 and a 52 week high of $56.6. The company has a market cap of $96.90 billion and a P/E ratio of 85.63.
Get the latest Abbott Laboratories (NYSE:ABT) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post BMO Capital Markets Maintains $5.00 Price Objective On Abbott Laboratories (NYSE:ABT), Maintains “Market Perform” Rating appeared first on Octafinance.